Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Review

Page Path
HOME > Article category > Review
314 Review
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Reviews
Others
Article image
Differences between Type 2 Diabetes Mellitus and Obesity Management: Medical, Social, and Public Health Perspectives
Soo Lim, Ga Eun Nam, Arya M. Sharma
Received April 2, 2025  Accepted May 6, 2025  Published online June 11, 2025  
DOI: https://doi.org/10.4093/dmj.2025.0278    [Epub ahead of print]
  • 334 View
  • 43 Download
AbstractAbstract PDFPubReader   ePub   
Obesity and type 2 diabetes mellitus (T2DM) are among the most urgent global public health challenges, yet differ markedly in recognition and management across medical, social, infrastructure, and policy domains. T2DM is supported by clear diagnostic criteria, defined treatment targets, and broad acceptance as a chronic disease. In contrast, obesity is assessed using imprecise metrics like body mass index, lacks standardized treatment goals, and is often misunderstood as a lifestyle issue rather than a chronic, relapsing disease. This misconception contributes to stigma, discrimination, and unrealistic patient expectations. T2DM receives substantial research funding, comprehensive clinical guidelines, and structured medical education, with strong support from large professional societies and multidisciplinary care models. Obesity care remains underfunded, inconsistently delivered, and underrepresented in medical training. Public health and policy efforts strongly favor T2DM, providing coordinated programs, insurance coverage, and regulatory oversight. Conversely, obesity is marginalized, with limited policy influence and a largely unregulated commercial weight-loss industry. Bridging these disparities requires adopting lessons from T2DM management—such as evidence-based guidelines, improved provider training, expanded insurance coverage, and public health strategies—to enhance obesity care and recognize it as a chronic disease requiring long-term, structured management.
Pharmacotherapy
Article image
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
Jae Hyun Bae
Diabetes Metab J. 2025;49(3):386-402.   Published online May 1, 2025
DOI: https://doi.org/10.4093/dmj.2025.0220
  • 4,650 View
  • 702 Download
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease and significantly increases cardiovascular risk and mortality. Despite conventional therapies, including renin-angiotensin-aldosterone system inhibitors, substantial residual risk remains. The emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists has reshaped DKD management. Beyond glycemic control, these agents provide distinct and complementary cardiorenal benefits through mechanisms such as hemodynamic modulation, anti-inflammatory effects, and metabolic adaptations. Landmark trials, including CREDENCE, DAPA-CKD, EMPA-KIDNEY, and FLOW, have demonstrated their efficacy in preserving kidney function and reducing adverse outcomes. SGLT2 inhibitors appear more effective in mitigating glomerular hyperfiltration and lowering heart failure risk, whereas GLP-1 receptor agonists are particularly beneficial in reducing albuminuria and atherosclerotic cardiovascular events. Although indirect comparisons suggest that SGLT2 inhibitors may offer greater protection against kidney function decline, direct head-to-head trials are lacking. Combination therapy holds promise, however further studies are needed to define optimal treatment strategies. This review synthesizes current evidence, evaluates comparative effectiveness, and outlines future directions in DKD management, emphasizing precision medicine approaches to enhance clinical outcomes. The integration of these therapies represents a paradigm shift in diabetes care, expanding treatment options for people with diabetes mellitus at risk of kidney failure.

Citations

Citations to this article as recorded by  
  • Special Issue “Molecular Therapeutics for Diabetes and Related Complications”
    Kota V. Ramana
    International Journal of Molecular Sciences.2025; 26(12): 5585.     CrossRef
Basic and Translational Research
Article image
Metabolic Sparks in the Liver: Metabolic and Epigenetic Reprogramming in Hepatic Stellate Cells Activation and Its Implications for Human Metabolic Diseases
Yeon Jin Roh, Hyeonki Kim, Dong Wook Choi
Diabetes Metab J. 2025;49(3):368-385.   Published online May 1, 2025
DOI: https://doi.org/10.4093/dmj.2025.0195
  • 1,400 View
  • 91 Download
AbstractAbstract PDFPubReader   ePub   
The liver plays a fundamental role in metabolic homeostasis, integrating systemic fuel utilization with the progression of various metabolic diseases. Hepatic stellate cells (HSCs) are a key nonparenchymal cell type in the liver, which is essential for maintaining hepatic architecture in their quiescent state. However, upon chronic liver injury or metabolic stress, HSCs become activated, leading to excessive extracellular matrix deposition and pro-fibrotic signaling, ultimately positioning them as key players in liver pathology. Emerging evidence highlights the critical roles of metabolic reprogramming and epigenetic regulation in HSCs activation. HSCs activation is driven by both intrinsic fuel metabolism reprogramming and extrinsic metabolic cues from the microenvironment, while the metabolic intermediates actively reshape the epigenetic landscape, reinforcing fibrogenic transcriptional programs. In this review, we summarize recent advances in understanding how metabolic and epigenetic alterations drive HSCs activation, thereby shaping transcriptional programs that sustain fibrosis, and discuss potential therapeutic strategies to target these interconnected pathways in human metabolic diseases.
Basic and Translational Research
Article image
Extracellular Vesicle-Mediated Network in the Pathogenesis of Obesity, Diabetes, Steatotic Liver Disease, and Cardiovascular Disease
Joonyub Lee, Won Gun Choi, Marie Rhee, Seung-Hwan Lee
Diabetes Metab J. 2025;49(3):348-367.   Published online May 1, 2025
DOI: https://doi.org/10.4093/dmj.2025.0184
  • 1,641 View
  • 120 Download
AbstractAbstract PDFPubReader   ePub   
Extracellular vesicles (EVs) are lipid bilayer-enclosed particles carrying bioactive cargo, including nucleic acids, proteins, and lipids, facilitating intercellular and interorgan communication. In addition to traditional mediators such as hormones, metabolites, and cytokines, increasing evidence suggests that EVs are key modulators in various physiological and pathological processes, particularly influencing metabolic homeostasis and contributing to the progression of cardiometabolic diseases. This review provides an overview of the most recent insights into EV-mediated mechanisms involved in the pathogenesis of obesity, insulin resistance, diabetes mellitus, steatotic liver disease, atherosclerosis, and cardiovascular disease. EVs play a critical role in modulating insulin sensitivity, glucose homeostasis, systemic inflammation, and vascular health by transferring functional molecules to target cells. Understanding the EV-mediated network offers potential for identifying novel biomarkers and therapeutic targets, providing opportunities for EV-based interventions in cardiometabolic disease management. Although many challenges remain, this evolving field highlights the need for further research into EV biology and its translational applications in cardiovascular and metabolic health.
Basic and Translational Research
Article image
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
Joon Seok Park, Kyu Sik Kim, Hyung Jin Choi
Diabetes Metab J. 2025;49(3):333-347.   Published online May 1, 2025
DOI: https://doi.org/10.4093/dmj.2025.0106
  • 2,257 View
  • 192 Download
AbstractAbstract PDFPubReader   ePub   
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as blockbuster drugs for treating metabolic diseases. Glucagon-like peptide-1 (GLP-1) plays a pivotal role in glucose homeostasis by enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and acting on the central nervous system to regulate satiation and satiety. This review summarizes the discovery of GLP-1 and the development of GLP-1RAs, with a particular focus on their central mechanisms of action. Human neuroimaging studies demonstrate that GLP-1RAs influence brain activity during food cognition, supporting a role in pre-ingestive satiation. Animal studies on hypothalamic feed-forward regulation of hunger suggest that cognitive hypothalamic mechanisms may also contribute to satiation control. We highlight the brain mechanisms of GLP-1RA-induced satiation and satiety, including cognitive impacts, with an emphasis on animal studies of hypothalamic glucagon-like peptide-1 receptor (GLP-1R) and GLP-1R-expressing neurons. Actions in non-hypothalamic regions are also discussed. Additionally, we review emerging combination drugs and oral GLP-1RA formulations aimed at improving efficacy and patient adherence. In conclusion, the dorsomedial hypothalamus (DMH)—a key GLP-1RA target—mediates pre-ingestive cognitive satiation, while other hypothalamic GLP-1R neurons regulate diverse aspects of feeding behavior, offering potential therapeutic targets for obesity treatment.
Others
Article image
Big Data Research for Diabetes-Related Diseases Using the Korean National Health Information Database
Kyung-Soo Kim, Bongseong Kim, Kyungdo Han
Diabetes Metab J. 2025;49(1):13-21.   Published online January 1, 2025
DOI: https://doi.org/10.4093/dmj.2024.0780
  • 2,514 View
  • 212 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
The Korean National Health Information Database (NHID), which contains nationwide real-world claims data including sociodemographic data, health care utilization data, health screening data, and healthcare provider information, is a powerful resource to test various hypotheses. It is also longitudinal in nature due to the recommended health checkup every 2 years and is appropriate for long-term follow-up study as well as evaluating the relationships between health outcomes and changes in parameters such as lifestyle factors, anthropometric measurements, and laboratory results. However, because these data are not collected for research purposes, precise operational definitions of diseases are required to facilitate big data analysis using the Korean NHID. In this review, we describe the characteristics of the Korean NHID, operational definitions of diseases used for research related to diabetes, and introduce representative research for diabetes-related diseases using the Korean NHID.

Citations

Citations to this article as recorded by  
  • Prevalence, Incidence, and Metabolic Characteristics of Young Adults with Type 2 Diabetes Mellitus in South Korea (2010–2020)
    Ji Yoon Kim, Jiyoon Lee, Joon Ho Moon, Se Eun Park, Seung-Hyun Ko, Sung Hee Choi, Nam Hoon Kim
    Diabetes & Metabolism Journal.2025; 49(2): 172.     CrossRef
Lifestyle
Article image
Ultra-Processed Foods and the Impact on Cardiometabolic Health: The Role of Diet Quality
Xiaowen Wang, Qi Sun
Diabetes Metab J. 2024;48(6):1047-1055.   Published online November 1, 2024
DOI: https://doi.org/10.4093/dmj.2024.0659
  • 9,592 View
  • 276 Download
  • 2 Web of Science
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
The consumption of ultra-processed foods (UPFs) has surged globally, raising significant public health concerns due to their associations with a range of adverse health outcomes. This review aims to elucidate potential health impacts of UPF intake and underscore the importance of considering diet quality when interpreting study findings. UPF group, as classified by the Nova system based on the extent of industrial processing, contains numerous individual food items with a wide spectrum of nutrient profiles, as well as differential quality as reflected by their potential health effects. The quality of a given food may well misalign with the processing levels so that a UPF food can be nutritious and healthful whereas a non-UPF food can be of low quality and excess intake of which may lead to adverse health consequences. The current review argues that it is critical to focus on the nutritional content and quality of foods and their role within the overall dietary pattern rather than only the level of processing. Further research should dissect health effects of diet quality and food processing, investigate the health impacts of ingredients that render the UPF categorization, understand roles of metabolomics and the gut microbiome in mediating and modulating the health effects of food processing, and consider environmental sustainability in UPF studies. Emphasizing nutrient-dense healthful foods and dietary patterns shall remain the pivotal strategy for promoting overall health and preventing chronic diseases.

Citations

Citations to this article as recorded by  
  • Social determinants of health and type 2 diabetes in Asia
    Kyunghun Sung, Seung‐Hwan Lee
    Journal of Diabetes Investigation.2025;[Epub]     CrossRef
Complications
Article image
Rate-Dependent Depression of the Hoffmann Reflex: Practical Applications in Painful Diabetic Neuropathy
Lu Han, Nigel A. Calcutt, Xiajun Zhou
Diabetes Metab J. 2024;48(6):1029-1046.   Published online November 1, 2024
DOI: https://doi.org/10.4093/dmj.2024.0614
  • 3,168 View
  • 141 Download
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
Measurement of the rate-dependent depression (RDD) of the Hoffmann (H) reflex, a technique developed over half a century ago, is founded on repeated stimulation of the H-reflex with tracking of sequentially evoked H-wave amplitudes in the resulting electromyogram. RDD offers insight into the integrity of spinal reflex pathways and spinal inhibitory regulation. Initially, RDD was predominantly utilized in the mechanistic exploration and evaluation of movement disorders characterized by spasticity symptoms, as may occur following spinal cord injury. However, there is increasing recognition that sensory input from the periphery is modified at the spinal level before ascending to the higher central nervous system and that some pain states can arise from, or be exaggerated by, disruption of spinal processing via a mechanism termed spinal disinhibition. This, along with the urgent clinical need to identify biological markers of pain generator and/or amplifier sites to facilitate targeted pain therapies, has prompted interest in RDD as a biomarker for the contribution of spinal disinhibition to neuropathic pain states. Current research in animals and humans with diabetes has revealed specific disorders of spinal GABAergic function associated with impaired RDD. Future investigations on RDD aim to further elucidate its underlying pathways and enhance its clinical applications.

Citations

Citations to this article as recorded by  
  • Mechanisms of Different Motor Neurons in the Occurrence of Spasticity After Spinal Cord Injury: A Narrative Review
    Han Gong, Ze-Yan Zhang, Zhi-Xuan Duan, Xin-Ao Mao, Yuan-Yuan Wu, Jia-Sheng Rao, Xiao-Xia Du
    International Journal of Molecular Sciences.2025; 26(11): 5162.     CrossRef
Guideline/Fact Sheet
Article image
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Jaehyun Bae, Eugene Han, Hye Won Lee, Cheol-Young Park, Choon Hee Chung, Dae Ho Lee, Eun-Hee Cho, Eun-Jung Rhee, Ji Hee Yu, Ji Hyun Park, Ji-Cheol Bae, Jung Hwan Park, Kyung Mook Choi, Kyung-Soo Kim, Mi Hae Seo, Minyoung Lee, Nan-Hee Kim, So Hun Kim, Won-Young Lee, Woo Je Lee, Yeon-Kyung Choi, Yong-ho Lee, You-Cheol Hwang, Young Sang Lyu, Byung-Wan Lee, Bong-Soo Cha, on Behalf of the Fatty Liver Research Group of the Korean Diabetes Association
Diabetes Metab J. 2024;48(6):1015-1028.   Published online November 1, 2024
DOI: https://doi.org/10.4093/dmj.2024.0541
  • 4,959 View
  • 353 Download
  • 2 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Since the role of the liver in metabolic dysfunction, including type 2 diabetes mellitus, was demonstrated, studies on non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) have shown associations between fatty liver disease and other metabolic diseases. Unlike the exclusionary diagnostic criteria of NAFLD, MAFLD diagnosis is based on the presence of metabolic dysregulation in fatty liver disease. Renaming NAFLD as MAFLD also introduced simpler diagnostic criteria. In 2023, a new nomenclature, steatotic liver disease (SLD), was proposed. Similar to MAFLD, SLD diagnosis is based on the presence of hepatic steatosis with at least one cardiometabolic dysfunction. SLD is categorized into metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related/-associated liver disease, alcoholrelated liver disease, specific etiology SLD, and cryptogenic SLD. The term MASLD has been adopted by a number of leading national and international societies due to its concise diagnostic criteria, exclusion of other concomitant liver diseases, and lack of stigmatizing terms. This article reviews the diagnostic criteria, clinical relevance, and differences among NAFLD, MAFLD, and MASLD from a diabetologist’s perspective and provides a rationale for adopting SLD/MASLD in the Fatty Liver Research Group of the Korean Diabetes Association.

Citations

Citations to this article as recorded by  
  • Bioelectrical impedance analysis parameters are superior to liver enzymes in predicting metabolic dysfunction-associated steatotic liver disease in young adults
    Kyungchul Song, Yu-Jin Kwon, Eunju Lee, Hye Sun Lee, Young Hoon Youn, Su Jung Baik, Hana Lee, Joon Young Kim, Youngha Choi, Hyun Wook Chae
    Internal and Emergency Medicine.2025; 20(3): 785.     CrossRef
  • Extracellular Vesicle-Mediated Network in the Pathogenesis of Obesity, Diabetes, Steatotic Liver Disease, and Cardiovascular Disease
    Joonyub Lee, Won Gun Choi, Marie Rhee, Seung-Hwan Lee
    Diabetes & Metabolism Journal.2025; 49(3): 348.     CrossRef
  • SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
    Jae Hyun Bae
    Diabetes & Metabolism Journal.2025; 49(3): 386.     CrossRef
Basic Research
Article image
Systems Biology of Human Microbiome for the Prediction of Personal Glycaemic Response
Nikhil Kirtipal, Youngchang Seo, Jangwon Son, Sunjae Lee
Diabetes Metab J. 2024;48(5):821-836.   Published online September 1, 2024
DOI: https://doi.org/10.4093/dmj.2024.0382
  • 5,391 View
  • 357 Download
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
The human gut microbiota is increasingly recognized as a pivotal factor in diabetes management, playing a significant role in the body’s response to treatment. However, it is important to understand that long-term usage of medicines like metformin and other diabetic treatments can result in problems, gastrointestinal discomfort, and dysbiosis of the gut flora. Advanced sequencing technologies have improved our understanding of the gut microbiome’s role in diabetes, uncovering complex interactions between microbial composition and metabolic health. We explore how the gut microbiota affects glucose metabolism and insulin sensitivity by examining a variety of -omics data, including genomics, transcriptomics, epigenomics, proteomics, metabolomics, and metagenomics. Machine learning algorithms and genome-scale modeling are now being applied to find microbiological biomarkers associated with diabetes risk, predicted disease progression, and guide customized therapy. This study holds promise for specialized diabetic therapy. Despite significant advances, some concerns remain unanswered, including understanding the complex relationship between diabetes etiology and gut microbiota, as well as developing user-friendly technological innovations. This mini-review explores the relationship between multiomics, precision medicine, and machine learning to improve our understanding of the gut microbiome’s function in diabetes. In the era of precision medicine, the ultimate goal is to improve patient outcomes through personalized treatments.

Citations

Citations to this article as recorded by  
  • On Gastronomic Jurisprudence and Judicial Wellness as a Matter of Competence
    Alan C. Logan, Colleen M. Berryessa, Pragya Mishra, Susan L. Prescott
    Laws.2025; 14(3): 39.     CrossRef
Drug/Regimen
Article image
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Ja Young Jeon, Dae Jung Kim
Diabetes Metab J. 2024;48(5):837-846.   Published online September 1, 2024
DOI: https://doi.org/10.4093/dmj.2024.0317
  • 6,891 View
  • 550 Download
  • 2 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
People with type 2 diabetes mellitus (T2DM) are at higher risk of developing cardiovascular disease, heart failure, chronic kidney disease, and premature death than people without diabetes. Therefore, treatment of diabetes aims to reduce these complications. Sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown beneficial effects on cardiorenal and metabolic health beyond glucose control, making them a promising class of drugs for achieving the ultimate goals of diabetes treatment. However, despite their proven benefits, the use of SGLT2 inhibitors in eligible patients with T2DM remains suboptimal due to reports of adverse events. The use of SGLT2 inhibitors is particularly limited in older patients with T2DM because of the lack of treatment experience and insufficient long-term safety data. This article comprehensively reviews the risk-benefit profile of SGLT2 inhibitors in older patients with T2DM, drawing on data from prospective randomized controlled trials of cardiorenal outcomes, original studies, subgroup analyses across different age groups, and observational cohort studies.

Citations

Citations to this article as recorded by  
  • Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
    Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim
    Journal of Diabetes Investigation.2025; 16(2): 215.     CrossRef
  • Pharmacological management of diabetes in older adults
    Junghyun Noh
    Cardiovascular Prevention and Pharmacotherapy.2025; 7(1): 13.     CrossRef
  • Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)—Special Interest Group in Diabetes
    Virginia Boccardi, Gülistan Bahat, Cafer Balci, Isabelle Bourdel-Marchasson, Antoine Christiaens, Lorenzo Maria Donini, Sibel Cavdar, Stefania Maggi, Serdar Özkök, Tajana Pavic, Stany Perkisas, Stefano Volpato, Muhammad Shoaib Zaidi, Andrej Zeyfang, Alan
    European Geriatric Medicine.2025;[Epub]     CrossRef
Cardiovascular Risk/Epidemiology
Article image
Artificial Light at Night and Type 2 Diabetes Mellitus
Jong-Ha Baek, Yong Zhu, Chandra L. Jackson, Yong-Moon Mark Park
Diabetes Metab J. 2024;48(5):847-863.   Published online September 1, 2024
DOI: https://doi.org/10.4093/dmj.2024.0237
  • 13,592 View
  • 396 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
The widespread and pervasive use of artificial light at night (ALAN) in our modern 24-hour society has emerged as a substantial disruptor of natural circadian rhythms, potentially leading to a rise in unhealthy lifestyle-related behaviors (e.g., poor sleep; shift work). This phenomenon has been associated with an increased risk of type 2 diabetes mellitus (T2DM), which is a pressing global public health concern. However, to date, reviews summarizing associations between ALAN and T2DM have primarily focused on the limited characteristics of exposure (e.g., intensity) to ALAN. This literature review extends beyond prior reviews by consolidating recent studies from 2000 to 2024 regarding associations between both indoor and outdoor ALAN exposure and the incidence or prevalence of T2DM. We also described potential biological mechanisms through which ALAN modulates glucose metabolism. Furthermore, we outlined knowledge gaps and investigated how various ALAN characteristics beyond only light intensity (including light type, timing, duration, wavelength, and individual sensitivity) influence T2DM risk. Recognizing the detrimental impact of ALAN on sleep health and the behavioral correlates of physical activity and dietary patterns, we additionally summarized studies investigating the potential mediating role of each component in the relationship between ALAN and glucose metabolism. Lastly, we proposed implications of chronotherapies and chrononutrition for diabetes management in the context of ALAN exposure.

Citations

Citations to this article as recorded by  
  • Impact of bedroom light exposure on glucose metabolic markers and the role of circadian-dependent meal timing: A population-based cross-sectional study
    Qi Li, Yu-xiang Xu, Xiu-zhen Lu, Yu-ting Shen, Yu-hui Wan, Pu-yu Su, Fang-biao Tao, Xin Chen, Ying Sun
    Ecotoxicology and Environmental Safety.2025; 290: 117589.     CrossRef
  • The impact of environmental pollution on metabolic health and the risk of non-communicable chronic metabolic diseases in humans
    Caterina Formichi, Sonia Caprio, Laura Nigi, Francesco Dotta
    Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(6): 103975.     CrossRef
  • Synergistic effects of air pollution and artificial light at night on diabetes risk: A prospective cohort study
    Desong Wen, Fei Lin, Chaowei Zhang, Ziyu Ge, Xiaohang Li, Zhenzhou Liu, Hanqing Zhao, Weimin Wang, Zhigang Chen, Guoan Zhao
    Environmental Pollution.2025; 379: 126472.     CrossRef
  • Circadian Deregulation: Back Facing the Sun Toward Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Development
    Mariana Verdelho Machado
    Nutrients.2024; 16(24): 4294.     CrossRef
Others
Article image
T-Cell Senescence in Human Metabolic Diseases
Ha Thi Nga, Thi Linh Nguyen, Hyon-Seung Yi
Diabetes Metab J. 2024;48(5):864-881.   Published online August 28, 2024
DOI: https://doi.org/10.4093/dmj.2024.0140
  • 9,154 View
  • 334 Download
  • 4 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   ePub   
Immunosenescence denotes a state of dysregulated immune cell function characterized by a confluence of factors, including arrested cell cycle, telomere shortening, markers of cellular stress, mitochondrial dysfunction, loss of proteostasis, epigenetic reprogramming, and secretion of proinflammatory mediators. This state primarily manifests during the aging process but can also be induced in various pathological conditions, encompassing chronic viral infections, autoimmune diseases, and metabolic disorders. Age-associated immune system alterations extend to innate and adaptive immune cells, with T-cells exhibiting heightened susceptibility to immunosenescence. In particular, senescent T-cells have been identified in the context of metabolic disorders such as obesity, diabetes, and cardiovascular diseases. Recent investigations suggest a direct link between T-cell senescence, inflammation, and insulin resistance. The perturbation of biological homeostasis by senescent T-cells appears intricately linked to the initiation and progression of metabolic diseases, particularly through inflammation-mediated insulin resistance. Consequently, senescent T-cells are emerging as a noteworthy therapeutic target. This review aims to elucidate the intricate relationship between metabolic diseases and T-cell senescence, providing insights into the potential roles of senescent T-cells in the pathogenesis of metabolic disorders. Through a comprehensive examination of current research findings, this review seeks to contribute to a deeper understanding of the complex interplay between immunosenescence and metabolic health.

Citations

Citations to this article as recorded by  
  • Immunomodulation for accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus
    Elena Bartoloni, Fabio Cacciapaglia, Gian Luca Erre, Elisa Gremese, Andreina Manfredi, Matteo Piga, Garifallia Sakellariou, Francesca Romana Spinelli, Ombretta Viapiana, Fabiola Atzeni
    Autoimmunity Reviews.2025; 24(4): 103760.     CrossRef
  • CD8+CD28+PD1− T Cells as a Prognostic Biomarker in Endometrial Cancer
    Yufei Nie, Lin Yang, Yanan Zhang, Hongyan Guo
    Current Oncology.2025; 32(3): 121.     CrossRef
  • T cell aging and exhaustion: Mechanisms and clinical implications
    Weiqi Zhang, Dejun Kong, Xiaohan Zhang, Lu Hu, Yeqi Nian, Zhongyang Shen
    Clinical Immunology.2025; 275: 110486.     CrossRef
  • Global research trends in inflammaging from 2005 to 2024: a bibliometric analysis
    Beier Jiang, Yi-ni Dong, Yu Xiong, Chun-xia Jiang, Jun Ping, Qi Wu, Liu-jun Xu, Run-zhe Shu, Dan-dan Gao, Sheng-mei Zhu, Wei-dong Ye, Feng Zhang
    Frontiers in Aging.2025;[Epub]     CrossRef
  • Immune cell dysfunction: A critical player in development of diabetes complications
    Mohamed J. Saadh, Omer Qutaiba B. Allela, Radhwan Abdul Kareem, Ashishkumar Kyada, H. Malathi, Deepak Nathiya, Deepak Bhanot, Hayder Naji Sameer, Atheer Khdyair Hamad, Zainab H. Athab, Mohaned Adil
    Current Research in Translational Medicine.2025; 73(3): 103510.     CrossRef
  • The immune health assessment technique of the elderly population and its application and promotion in the prevention and treatment of common aged diseases
    Qing Li, Ling-bing Meng
    Journal of Aging and Rehabilitation.2024; 1(4): 93.     CrossRef
Others
Article image
Holistic and Personalized Strategies for Managing in Elderly Type 2 Diabetes Patients
Jae-Seung Yun, Kyuho Kim, Yu-Bae Ahn, Kyungdo Han, Seung-Hyun Ko
Diabetes Metab J. 2024;48(4):531-545.   Published online July 26, 2024
DOI: https://doi.org/10.4093/dmj.2024.0310
  • 12,106 View
  • 480 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Due to increased life expectancy and lifestyle changes, the prevalence of diabetes among the elderly in Korea is continuously rising, as is the associated public health burden. Diabetes management in elderly patients is complicated by age-related physiological changes, sarcopenia characterized by loss of muscle mass and function, comorbidities, and varying levels of functional, cognitive, and mobility abilities that lead to frailty. Moreover, elderly patients with diabetes frequently face multiple chronic conditions that elevate their risk of cardiovascular diseases, cancer, and mortality; they are also prone to complications such as hyperglycemic hyperosmolar state, diabetic ketoacidosis, and severe hypoglycemia. This review examines the characteristics of and management approaches for diabetes in the elderly, and advocates for a comprehensive yet personalized strategy.

Citations

Citations to this article as recorded by  
  • Diabetes Fact Sheets in Korea 2024
    Se Eun Park, Seung-Hyun Ko, Ji Yoon Kim, Kyuho Kim, Joon Ho Moon, Nam Hoon Kim, Kyung Do Han, Sung Hee Choi, Bong Soo Cha
    Diabetes & Metabolism Journal.2025; 49(1): 24.     CrossRef
  • The effect of multidisciplinary team and experience-based co-design on the care of older adult patients with type 2 diabetes: A randomized controlled trial
    Yujun Zhuang, Hongjiang Ye, Xiaoyan Yang, Lifang Zheng, Zhizhen Chen, Jianjia Jiang, Lunpan Mou, Pingping Li, Jiawei Qin, Yaduan Dai, Yanling Mao
    Diabetes Research and Clinical Practice.2025; 221: 112028.     CrossRef
  • Older Adults with Diabetes in Korea: Latest Clinical and Epidemiologic Trends
    Kyuho Kim, Bongseong Kim, Kyuna Lee, Yu-Bae Ahn, Seung-Hyun Ko, Sung Hee Choi, Kyungdo Han, Jae-Seung Yun
    Diabetes & Metabolism Journal.2025; 49(2): 183.     CrossRef
Others
Article image
Korean National Burden of Disease: The Importance of Diabetes Management
Chung-Nyun Kim, Yoon-Sun Jung, Young-Eun Kim, Minsu Ock, Seok-Jun Yoon
Diabetes Metab J. 2024;48(4):518-530.   Published online July 26, 2024
DOI: https://doi.org/10.4093/dmj.2024.0087
  • 6,334 View
  • 252 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
Diagnosing the current health status and disease burden in a population is crucial for public health interventions. The ability to compare the burden of different diseases through a single measure, such as disability-adjusted life years has become feasible and continues to be produced and updated through the Global Burden of Diseases (GBD) study. However, the disease burden values of the GBD study do not accurately reflect the unique situation in a specific country with various circumstances. In response, the Korean National Burden of Disease (KNBD) study was conducted to estimate the disease burden in Koreans by considering Korea’s cultural context and utilizing the available data sources at the national level. Both studies identified non-communicable diseases, such as diabetes mellitus (DM), as the primary cause of disease burden among Koreans. However, the extent of public health interventions currently being conducted by the central and local governments does not align with the severity of the disease burden. This review suggests that despite the high burden of DM in South Korea, the current policies may not fully address its impact, underscoring the need for expanded chronic disease management programs and a shift towards prevention-focused healthcare paradigms.

Citations

Citations to this article as recorded by  
  • Diabetes Fact Sheets in Korea 2024
    Se Eun Park, Seung-Hyun Ko, Ji Yoon Kim, Kyuho Kim, Joon Ho Moon, Nam Hoon Kim, Kyung Do Han, Sung Hee Choi, Bong Soo Cha
    Diabetes & Metabolism Journal.2025; 49(1): 24.     CrossRef
  • Reinforcing Primary Care in Korea: Policy Implications, Data Sources, and Research Methods
    Chung-Nyun Kim, Seok-Jun Yoon
    Journal of Korean Medical Science.2025;[Epub]     CrossRef
  • Older Adults with Diabetes in Korea: Latest Clinical and Epidemiologic Trends
    Kyuho Kim, Bongseong Kim, Kyuna Lee, Yu-Bae Ahn, Seung-Hyun Ko, Sung Hee Choi, Kyungdo Han, Jae-Seung Yun
    Diabetes & Metabolism Journal.2025; 49(2): 183.     CrossRef
  • Social determinants of health and type 2 diabetes in Asia
    Kyunghun Sung, Seung‐Hwan Lee
    Journal of Diabetes Investigation.2025;[Epub]     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP